July 17, 2017 / 9:05 PM / 4 days ago

BRIEF-Paratek says Omadacycline showed high clinical success rates for infections by Absssi pathogens

1 Min Read

July 17 (Reuters) - Paratek Pharmaceuticals Inc

* Says phase 3 study of oral-only dosing of Omadacycline met all primary, secondary endpoints in acute bacterial skin infections

* Omadacycline generally safe, well tolerated; showed high clinical success rates for infections by most common Absssi pathogens Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below